Metformin–Glimepiride heterocomplex

The Metformin–Glimepiride heterocomplex is a pharmacological combination of two distinct anti-diabetic agents, metformin and glimepiride, rather than a single biological target such as a receptor or enzyme (Rena et al., 2017). Metformin is a biguanide that primarily reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial respiration (Madiraju et al., 2014). Glimepiride is a third-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor 1 (SUR1) and closing ATP-sensitive potassium channels (Sola et al., 2015). This combination is used clinically to provide complementary mechanisms of action for the management of type 2 diabetes mellitus, addressing both insulin resistance and impaired insulin secretion (FDA, 2021). While the term 'heterocomplex' may be used in pharmaceutical science to describe a specific physical or chemical association between the two drugs for formulation purposes, the therapeutic effects are achieved through the interaction of the individual drugs with their respective biological targets.

Other names

Metformin-Glimepiride combinationMetformin-Glimepiride co-crystalMetformin-Glimepiride fixed-dose combinationMetformin/Glimepiride

Metformin activates AMP-activated protein kinase (AMPK) and inhibits mitochondrial glycerol-3-phosphate dehydrogenase (GPD2) to reduce hepatic glucose output; Glimepiride binds to the sulfonylurea receptor 1 (SUR1) subunit of ATP-sensitive potassium (KATP) channels to stimulate insulin release.